156 related articles for article (PubMed ID: 38443603)
1. Anti-tumor necrosis factor (aTNF) weaning strategy in juvenile idiopathic arthritis (JIA): does duration matter?
Teh KL; Das L; Book YX; Hoh SF; Gao X; Arkachaisri T
Clin Rheumatol; 2024 May; 43(5):1723-1733. PubMed ID: 38443603
[TBL] [Abstract][Full Text] [Related]
2. Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive Disease.
Lovell DJ; Johnson AL; Huang B; Gottlieb BS; Morris PW; Kimura Y; Onel K; Li SC; Grom AA; Taylor J; Brunner HI; Huggins JL; Nocton JJ; Haines KA; Edelheit BS; Shishov M; Jung LK; Williams CB; Tesher MS; Costanzo DM; Zemel LS; Dare JA; Passo MH; Ede KC; Olson JC; Cassidy EA; Griffin TA; Wagner-Weiner L; Weiss JE; Vogler LB; Rouster-Stevens KA; Beukelman T; Cron RQ; Kietz D; Schikler K; Schmidt KM; Mehta J; Wahezi DM; Ting TV; Verbsky JW; Eberhard BA; Spalding S; Chen C; Giannini EH
Arthritis Rheumatol; 2018 Sep; 70(9):1508-1518. PubMed ID: 29604189
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the outcomes between early and late anti-tumor necrosis factor therapy in patients with enthesitis-related subcategory of juvenile idiopathic arthritis: a multi-center study in Southeast Asia.
Vilaiyuk S; Lerkvaleekul B; Jino J; Charuvanij S; Book YX; Arkachaisri T
Expert Opin Biol Ther; 2022 Oct; 22(10):1323-1332. PubMed ID: 35876095
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors.
Gieling J; van den Bemt B; Hoppenreijs E; Schatorjé E
Pediatr Rheumatol Online J; 2022 Dec; 20(1):109. PubMed ID: 36471348
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study.
Heiligenhaus A; Klotsche J; Tappeiner C; Sengler C; Niewerth M; Liedmann I; Hoeft S; Walscheid K; Lavric M; Foell D; Minden K
Rheumatology (Oxford); 2019 Jun; 58(6):975-986. PubMed ID: 30590748
[TBL] [Abstract][Full Text] [Related]
6. Duration of inactive disease while off disease-modifying anti-rheumatic drugs seems to influence flare rates in juvenile idiopathic arthritis: an observational retrospective study.
Aires PP; Terreri MTRA; Silva VBM; Vieira MM; Len CA
Acta Reumatol Port; 2021; 46(2):120-125. PubMed ID: 34226433
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Flare Following Etanercept Withdrawal in Patients with Rheumatoid Factor-negative Juvenile Idiopathic Arthritis Who Reached Remission while Taking Medication.
Aquilani A; Marafon DP; Marasco E; Nicolai R; Messia V; Perfetti F; Magni-Manzoni S; De Benedetti F
J Rheumatol; 2018 Jul; 45(7):956-961. PubMed ID: 29717035
[TBL] [Abstract][Full Text] [Related]
8. Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy.
Hinze CH; Foell D; Johnson AL; Spalding SJ; Gottlieb BS; Morris PW; Kimura Y; Onel K; Li SC; Grom AA; Taylor J; Brunner HI; Huggins JL; Nocton JJ; Haines KA; Edelheit BS; Shishov M; Jung LK; Williams CB; Tesher MS; Costanzo DM; Zemel LS; Dare JA; Passo MH; Ede KC; Olson JC; Cassidy EA; Griffin TA; Wagner-Weiner L; Weiss JE; Vogler LB; Rouster-Stevens KA; Beukelman T; Cron RQ; Kietz D; Schikler K; Mehta J; Ting TV; Verbsky JW; Eberhard AB; Huang B; Giannini EH; Lovell DJ
Arthritis Rheumatol; 2019 Mar; 71(3):451-459. PubMed ID: 30225949
[TBL] [Abstract][Full Text] [Related]
9. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
Ramanan AV; Quartier P; Okamoto N; Foeldvari I; Spindler A; Fingerhutová Š; Antón J; Wang Z; Meszaros G; Araújo J; Liao R; Keller S; Brunner HI; Ruperto N; ;
Lancet; 2023 Aug; 402(10401):555-570. PubMed ID: 37423231
[TBL] [Abstract][Full Text] [Related]
10. Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching.
Brunelli JB; Silva CA; Pasoto SG; Saa CGS; Kozu KT; Goldenstein-Schainberg C; Leon EP; Vendramini MBG; Fontoura N; Bonfa E; Aikawa NE
Clin Rheumatol; 2020 Feb; 39(2):515-521. PubMed ID: 31707543
[TBL] [Abstract][Full Text] [Related]
11. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy.
Chang CY; Meyer RM; Reiff AO
Arthritis Care Res (Hoboken); 2015 May; 67(5):658-66. PubMed ID: 25220674
[TBL] [Abstract][Full Text] [Related]
12. Outcomes and predictors of juvenile idiopathic arthritis in Southeast Asia: a Singapore longitudinal study over a decade.
Teh KL; Tanya M; Das L; Hoh SF; Gao X; Arkachaisri T
Clin Rheumatol; 2021 Jun; 40(6):2339-2349. PubMed ID: 33236179
[TBL] [Abstract][Full Text] [Related]
13. Enthesitis-related arthritis is the most common category of juvenile idiopathic arthritis in Taiwan and presents persistent active disease.
Shih YJ; Yang YH; Lin CY; Chang CL; Chiang BL
Pediatr Rheumatol Online J; 2019 Aug; 17(1):58. PubMed ID: 31443722
[TBL] [Abstract][Full Text] [Related]
14. Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial.
Gerss J; Tedy M; Klein A; Horneff G; Miranda-Garcia M; Kessel C; Holzinger D; Stanevica V; Swart JF; Cabral DA; Brunner HI; Foell D
Ann Rheum Dis; 2022 Jul; 81(7):990-997. PubMed ID: 35260388
[TBL] [Abstract][Full Text] [Related]
15. Disease Recapture Rates After Medication Discontinuation and Flare in Juvenile Idiopathic Arthritis: An Observational Study Within the Childhood Arthritis and Rheumatology Research Alliance Registry.
Ringold S; Dennos AC; Kimura Y; Beukelman T; Shrader P; Phillips TA; Kohlheim M; Schanberg LE; Yeung RSM; Horton DB;
Arthritis Care Res (Hoboken); 2023 Apr; 75(4):715-723. PubMed ID: 35921198
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis.
Ramanan AV; Dick AD; Jones AP; McKay A; Williamson PR; Compeyrot-Lacassagne S; Hardwick B; Hickey H; Hughes D; Woo P; Benton D; Edelsten C; Beresford MW;
N Engl J Med; 2017 Apr; 376(17):1637-1646. PubMed ID: 28445659
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate.
Lovell DJ; Brunner HI; Reiff AO; Jung L; Jarosova K; Němcová D; Mouy R; Sandborg C; Bohnsack JF; Elewaut D; Gabriel C; Higgins G; Kone-Paut I; Jones OY; Vargová V; Chalom E; Wouters C; Lagunes I; Song Y; Martini A; Ruperto N
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665432
[TBL] [Abstract][Full Text] [Related]
18. The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort.
Guzman J; Oen K; Huber AM; Watanabe Duffy K; Boire G; Shiff N; Berard RA; Levy DM; Stringer E; Scuccimarri R; Morishita K; Johnson N; Cabral DA; Rosenberg AM; Larché M; Dancey P; Petty RE; Laxer RM; Silverman E; Miettunen P; Chetaille AL; Haddad E; Houghton K; Spiegel L; Turvey SE; Schmeling H; Lang B; Ellsworth J; Ramsey SE; Bruns A; Roth J; Campillo S; Benseler S; Chédeville G; Schneider R; Tse SM; Bolaria R; Gross K; Feldman B; Feldman D; Cameron B; Jurencak R; Dorval J; LeBlanc C; St Cyr C; Gibbon M; Yeung RS; Duffy CM; Tucker LB;
Ann Rheum Dis; 2016 Jun; 75(6):1092-8. PubMed ID: 25985972
[TBL] [Abstract][Full Text] [Related]
19. Use of MRP8/14 in clinical practice as a predictor of outcome after methotrexate withdrawal in patients with juvenile idiopathic arthritis.
Sumner EJ; Almeida B; Palman J; Bale P; Heard C; Holzinger D; Roth J; Foell D; Robinson E; Ursu S; Wallace C; Gilmour K; Wedderburn LR; Ralph E
Clin Rheumatol; 2022 Sep; 41(9):2825-2830. PubMed ID: 35486225
[TBL] [Abstract][Full Text] [Related]
20. The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis.
Walters HM; Pan N; Lehman TJ; Adams A; Kalliolias GD; Zhu YS; Santiago F; Nguyen J; Sitaras L; Cunningham-Rundles S; Walsh TJ; Toussi SS
Clin Exp Immunol; 2016 Jun; 184(3):308-17. PubMed ID: 26934060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
